PulseExploreJournal ClubTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 20, 2026Retina

Effectiveness and Safety of Biosimilar Anti-Vascular Endothelial Growth Factor for Retinal Diseases: A Systematic Review and Meta-Analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

BPBhadra U. PandyaAMAndrew Mihalache;RHRyan S. Huang

Discussion

Loading...

Member takes

Overview

A systematic review compares biosimilar and reference anti-VEGF outcomes in retinal diseases, suggesting similar effectiveness.

Key Points

  • This research aims to compare the effectiveness and safety of biosimilar anti-VEGF with reference anti-VEGF for retinal diseases.
  • Conducted a systematic review and meta-analysis of studies from 2015 to 2024.
  • Included studies focusing on the effectiveness and safety outcomes of biosimilar anti-VEGF.
  • Utilized a random effects model for meta-analysis.
  • Assessed risk of bias using Joanna Briggs Institute tools and evaluated evidence certainty with GRADE criteria.
  • Analyzed a total of 25 studies dealing with AMD, DME, RVO, and polypoidal choroidal vasculopathy.
  • No significant differences in visual acuity, retinal thickness, or adverse events between biosimilar and reference anti-VEGF.
  • Subgroup analyses did not reveal significant disparities in outcomes.
  • Findings are supported by moderate to high certainty evidence as per GRADE criteria.

Cite This Study

Pandya et al. (2026) studied this question.

synapsesocial.com/papers/6997fa5aad1d9b11b34537ffhttps://doi.org/10.1097/iae.0000000000004807
View Full Paper
Ask AI
Bookmark
Share